Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis

[1]  M. Inglese,et al.  Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis , 2021, Neurotherapeutics.

[2]  G. Pardo,et al.  Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data , 2021, Journal of managed care & specialty pharmacy.

[3]  A. Phillips,et al.  The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis , 2021, Journal of medical economics.

[4]  A. Sempere,et al.  Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population , 2020, Annals of clinical and translational neurology.

[5]  M. A. Pérez-San-Gregorio,et al.  Quality of life in adults with multiple sclerosis: a systematic review , 2020, BMJ Open.

[6]  R. Edwards,et al.  Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis , 2020, BMC Neurology.

[7]  K. Anja.  European Committee for Treatment and Research in Multiple Sclerosis , 2019, Kinder- und Jugendmedizin.

[8]  Ruth Ann Marrie,et al.  The prevalence of MS in the United States , 2019, Neurology.

[9]  P. Duquette,et al.  A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies , 2019, PloS one.

[10]  R. Mody,et al.  Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States , 2019, Diabetes, obesity & metabolism.

[11]  L. Wilkins.  Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology , 2019, Neurology.

[12]  F. Lublin,et al.  Clinical Course of Multiple Sclerosis. , 2018, Cold Spring Harbor perspectives in medicine.

[13]  V. Herrera,et al.  Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. , 2017, Journal of managed care & specialty pharmacy.

[14]  S. Patten,et al.  Depression in multiple sclerosis , 2017, International review of psychiatry.

[15]  A. Boster,et al.  Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database , 2017, Neurology and Therapy.

[16]  C. Carlin,et al.  Adherence to Disease-Modifying Therapies for Multiple Sclerosis , 2016, Journal of managed care & specialty pharmacy.

[17]  A. Farr,et al.  The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis , 2016, Journal of medical economics.

[18]  K. Myhr,et al.  Disease-modifying treatments for multiple sclerosis – a review of approved medications , 2015, European journal of neurology.

[19]  D. Irwin,et al.  Differences In Multiple Sclerosis Relapse Rates Based On Patient Adherence, Average Daily Dose, And Persistence With Disease-Modifying Therapy: Observations Based on Real-World Data. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  Jonathan D. Campbell,et al.  Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study. , 2015, Journal of managed care & specialty pharmacy.

[21]  Z. Katsarava,et al.  Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program , 2015, BMC Neurology.

[22]  D. Ollendorf,et al.  Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. , 2015, Journal of managed care pharmacy : JMCP.

[23]  M. Duh,et al.  Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis , 2015, Journal of medical economics.

[24]  G. Capkun,et al.  Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis , 2014, Journal of medical economics.

[25]  J. de Seze,et al.  Patient perceptions of multiple sclerosis and its treatment , 2012, Patient preference and adherence.

[26]  P. Fontoura,et al.  The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis , 2011, European journal of neurology.

[27]  F. Patti.  Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence , 2010, Patient preference and adherence.

[28]  Arthur L. Allen,et al.  Factors that influence adherence with disease-modifying therapy in MS , 2009, Journal of Neurology.

[29]  T. Dwyer,et al.  Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses , 2008, Pharmacoepidemiology and drug safety.

[30]  P. Panegyres,et al.  Cognitive impairment in multiple sclerosis: Evidence-based analysis and recommendations , 2007, Journal of Clinical Neuroscience.

[31]  J. S. Butler,et al.  Factors leading patients to discontinue multiple sclerosis therapies. , 2005, Journal of the American Pharmacists Association : JAPhA.

[32]  P. Federico,et al.  Adherence, Quality of Life, and General Satisfaction with Co-formulated Zidovudine, Lamivudine, and Abacavir on Antiretroviral-Experienced Patients , 2004 .

[33]  J. Virchow,et al.  Non-persistence and non-adherence to long-acting COPD medication therapy: A retrospective cohort study based on a large German claims dataset. , 2017, Respiratory medicine.

[34]  J. Menzin,et al.  Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis , 2013, Journal of managed care pharmacy : JMCP.

[35]  J. Stephenson,et al.  Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis , 2011, Advances in therapy.

[36]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[37]  Kathleen Costello,et al.  Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. , 2008, Medscape journal of medicine.

[38]  B. Clotet,et al.  Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. , 2004, HIV clinical trials.